PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-03. Numbers and descriptions here follow the published literature rather than marketing material.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Inherited – hereditary motor neuropathies, Charcot–Marie–Tooth disease, and hereditary neuropathy with liability to pressure palsy Acquired – diabetes mellitus, vascular neuropathy, alcohol use disorder, vitamin E deficiency, and vitamin B12 deficiency
=== Improving health care team outcomes === Undifferentiated connective tissue disease occurs for various reasons; underlying factors may affect several organs depending on individual sensitivity. Coordination of care between primary clinicians and experts (like rheumatologists) can help achieve optimal patient outcomes.
The bill passed by a bipartisan vote and prohibits pharmacy benefit managers from sending customers to pharmacies they have a financial interest in and from charging health insurance plans a higher price for a drug than what the pharmacy benefit managers pay the pharmacy.
=== Operation Inherent Resolve === On 19 December 2014, Stars & Stripes, a daily military newspaper, announced 1,000 soldiers from the 82nd Airborne's 3rd Brigade Combat Team would deploy to Iraq to train, advise, and assist Iraq's Security Forces. On 3 November 2016, it was reported that 1,700 soldiers from the 2d Brigade Combat Team will deploy to the US Central Command area of responsibility in Iraq, to take part in Operation Inherent Resolve. They will replace the 2d Brigade Combat Team, 101st Airborne Division and will advise and assist Iraqi Security Forces currently trying to retake Mosul from ISIS fighters. On 27 March 2017, it was reported that 300 paratroopers from the 82nd Airborne's 2nd Brigade Combat Team will temporarily deploy to northern Iraq to provide additional advise-and-assist combating ISIS, particularly to speed up the offensive against ISIS in Mosul. On 31 December 2019, approximately 750 soldiers from the 82nd Airborne's Immediate Response Force were authorized to be deployed to Iraq in response to events which saw the United States' embassy in the country stormed. From the start of January 2017 to September 2017, the division suffered the loss of five paratroopers killed in action.
==== Development ==== The length of time before hatching is highly variable; smaller eggs in warmer waters are the fastest to hatch, and newborns can emerge after as little as a few days. Larger eggs in colder waters can develop for over a year before hatching. The process from spawning to hatching follows a similar trajectory in all species, the main variable being the amount of yolk available to the young and when it is absorbed by the embryo. Unlike most other molluscs, cephalopods do not have a morphologically distinct larval stage. Instead, the juveniles of coleoids are known as paralarvae. Paralarvae have been observed only in members of the Octopoda and Teuthida (which constitutes the modern definition of Coleoidea). In contrast, hatchling nautili are not referred to by a specific technical term, as they resemble miniatures of the adults. Neonate cephalopods quickly learn how to hunt, using encounters with prey to refine their strategies. Growth in juveniles is usually allometric, whilst adult growth is isometric.
Sources: en.wikipedia.org
== History == IRIS was discovered in the 1980s when physicians noted paradoxical symptomatic worsening of patients being treated for pulmonary tuberculosis and leprosy. There was worsened fever, weight loss, shortness of breath, and fatigue in patients with pulmonary tuberculosis and worsened skin lesions in patients with leprosy. Though the mechanism was unclear at the time, these observations were attributed to a pro-inflammatory state brought on by starting treatment.
=== Toxicity === Ingesting less than 1.5 g (1⁄16 oz) of saffron is not toxic for humans, but doses greater than 5 g (3⁄16 oz) can become increasingly toxic. Mild toxicity includes dizziness, nausea, vomiting, and diarrhea, whereas at higher doses there can be reduced platelet count and spontaneous bleeding.
Avialans diversified into a wide variety of forms during the Cretaceous period. Many groups retained primitive characteristics, such as clawed wings and teeth, though the latter were lost independently in a number of avialan groups, including modern birds (Aves). Increasingly stiff tails (especially the outermost half) can be seen in the evolution of maniraptoromorphs, and this process culminated in the appearance of the pygostyle, an ossification of fused tail vertebrae. In the late Cretaceous, about 100 million years ago, the ancestors of all modern birds evolved a more open pelvis, allowing them to lay larger eggs compared to body size. Around 95 million years ago, they evolved a better sense of smell. A third stage of bird evolution starting with Ornithothoraces (the "bird-chested" avialans) can be associated with the refining of aerodynamics and flight capabilities, and the loss or co-ossification of several skeletal features. Particularly significant are the development of an enlarged, keeled sternum and the alula, and the loss of grasping hands.
Nature Communications, 6, 7564. https://doi.org/10.1038/ncomms8564 J. Su, P. Wang, W. Zhou, M. Peydayesh, J. Zhou, T. Jin, F. Donat, C. Jin, L. Xia, K. Wang, F. Ren, P. Van der Meeren, F. Pelayo García de Arquer & R. Mezzenga (2024). Single-site iron-anchored amyloid hydrogels as catalytic platforms for alcohol detoxification. Nature Nanotechnology, 19(8), 1168–1177. https://doi.org/10.1038/s41565-024-01657-7 J. Zhou, S. Gowachirapant, C. Zeder, A. Wieczorek, J. Guth, I. Kutzli, S. Siol, F. von Meyenn, M. B. Zimmermann & R. Mezzenga (2025). Oat protein nanofibril–iron hybrids offer a stable, high-absorption iron delivery platform for iron fortification. Nature Food, 6, 1164–1175. https://doi.org/10.1038/s43016-025-01260-6 J. Adamcik & R. Mezzenga (2018). Amyloid polymorphism in the protein folding and aggregation energy landscape. Angewandte Chemie International Edition, 57(28), 8370–8382. https://doi.org/10.1002/anie.201713416 D. Xu, J. Zhou, W.L. Soon, I. Kutzli, A. Molière, S. Diedrich, M. Radiom, S. Handschin, B. Li, L. Li, S. J. Sturla, C. Y. Ewald, R. Mezzenga (2023). Food amyloid fibrils are safe nutrition ingredients based on in-vitro and in-vivo assessment. Nature Communications, 14(1), 6806. https://doi.org/10.1038/s41467-023-42486-x
In June 2019, Pritzker signed into law Senate Bill 25, or the Reproductive Health Act. The act repealed the Illinois Abortion Law of 1975, which penalized doctors for performing abortions considered "unnecessary", and the "Partial-Birth Abortion Ban Act". The new bill ensured the "fundamental right to make autonomous decisions about one's own reproductive health", specifically the right to choose whether to carry a pregnancy to term or to terminate it, and denies a zygote, an embryo, or a fetus "independent rights under the law" of the State of Illinois. Pritzker encouraged other states that had passed restrictions on abortion to reconsider their positions and said that women from other states could access medical services in Illinois. After Dobbs v. Jackson overturned Roe v. Wade in 2022, Illinois became an abortion-access state for people in the South and Midwest whose states ban abortion, with 30% of abortions being for out-of-state residents. Abortions in Illinois increased by over 45% in the year after Roe was overturned, primarily due to patients' traveling from states with abortion bans. In 2024, Pritzker signed the Birth Equity Act, which required Illinois-based health insurance providers to cover abortion care without copayments or deductibles. On June 24, 2026, Pritzker signed the Reproductive Health Records Privacy Act, a law that protects those seeking abortions in Illinois by shielding digital medical records from out-of-state entities, effective July 1, 2027.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.